

# Eleonora Cocco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4252958/publications.pdf>

Version: 2024-02-01

246  
papers

6,558  
citations

76196

40  
h-index

114278

63  
g-index

253  
all docs

253  
docs citations

253  
times ranked

7388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>New England Journal of Medicine</i> , 2017, 376, 1615-1626.	13.9	301
2	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006, 12, 814-823.	1.4	206
3	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	2.7	184
4	Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. <i>Nature Genetics</i> , 2010, 42, 495-497.	9.4	164
5	Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. <i>PLoS ONE</i> , 2012, 7, e32487.	1.1	147
6	Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. <i>Human Molecular Genetics</i> , 2001, 10, 2907-2916.	1.4	134
7	Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. <i>Lancet, The</i> , 2002, 359, 1461-1465.	6.3	112
8	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.5	102
9	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014, 14, 171.	0.8	99
10	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
11	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	1.7	86
12	Association of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> with Multiple Sclerosis in Sardinian Patients. <i>PLoS ONE</i> , 2011, 6, e18482.	1.1	85
13	Familial effects on the clinical course of multiple sclerosis. <i>Neurology</i> , 2007, 68, 376-383.	1.5	77
14	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e832-e839.	1.5	74
15	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1225-1233.	1.4	72
16	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. <i>Annals of Neurology</i> , 2006, 59, 634-639.	2.8	69
17	Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. <i>Genes and Immunity</i> , 2009, 10, 15-17.	2.2	69
18	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011, 77, 1887-1895.	1.5	68

#	ARTICLE	IF	CITATIONS
19	<sup>1</sup> H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e185.	3.1	68
20	Epidemiology of multiple sclerosis in south-western Sardinia. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1282-1289.	1.4	66
21	Age at onset in multiple sclerosis. <i>Neurological Sciences</i> , 2000, 21, S825-S829.	0.9	65
22	Alemtuzumab long-term immunologic effect. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e194.	3.1	65
23	The risk of Bipolar Disorders in Multiple Sclerosis. <i>Journal of Affective Disorders</i> , 2014, 155, 255-260.	2.0	61
24	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 187-191.	0.9	61
25	Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 358, 339-344.	0.3	57
26	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	57
27	Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014, 270, 51-55.	1.1	56
28	Clinical activity after fingolimod cessation: disease reactivation or rebound?. <i>European Journal of Neurology</i> , 2018, 25, 1270-1275.	1.7	56
29	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. <i>EBioMedicine</i> , 2022, 80, 104042.	2.7	54
30	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1068-1070.	1.4	53
31	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	3.7	53
32	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
33	Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score. <i>Journal of the Neurological Sciences</i> , 2014, 345, 159-163.	0.3	52
34	Assessing association of comorbidities with treatment choice and persistence in MS. <i>Neurology</i> , 2017, 89, 2222-2229.	1.5	50
35	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. <i>BMC Neurology</i> , 2013, 13, 177.	0.8	48
36	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48

#	ARTICLE	IF	CITATIONS
37	Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by <i>LMNA</i> gene mutations. <i>Muscle and Nerve</i> , 2010, 41, 458-463.	1.0	44
38	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 93, 148-155.	1.2	44
39	“Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.	1.5	44
40	Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study. <i>PLoS ONE</i> , 2013, 8, e59711.	1.1	43
41	Epstein Barr Virus and <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> peptides are recognized in sera and cerebrospinal fluid of MS patients. <i>Scientific Reports</i> , 2016, 6, 22401.	1.6	42
42	Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 781843.	2.2	42
43	The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. <i>Human Molecular Genetics</i> , 2004, 13, 2919-2924.	1.4	41
44	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. <i>Journal of Affective Disorders</i> , 2014, 167, 192-197.	2.0	40
45	Walking improvements with nabiximols in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2472-2477.	1.8	40
46	Top-down proteomic profiling of human saliva in multiple sclerosis patients. <i>Journal of Proteomics</i> , 2018, 187, 212-222.	1.2	40
47	Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1200-1202.	1.4	39
48	Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. <i>Gait and Posture</i> , 2017, 58, 307-309.	0.6	39
49	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	2.1	39
50	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. <i>PLoS ONE</i> , 2012, 7, e41678.	1.1	38
51	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	3.7	38
52	Cerebrospinal fluid findings in Devic's neuromyelitis optica. <i>Neurological Sciences</i> , 2004, 25, s368-s370.	0.9	37
53	Human interferon regulatory factor 5 homologous epitopes of <i>Epstein-Barr</i> virus and <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> induce a specific humoral and cellular immune response in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015, 21, 984-995.	1.4	37
54	HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 327-327.	0.9	36

#	ARTICLE	IF	CITATIONS
55	The current role of mitoxantrone in the treatment of multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 607-616.	1.4	36
56	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	1.4	36
57	A novel Cx32 mutation causes X-linked Charcot-Marie-Tooth disease with brainstem involvement and brain magnetic resonance spectroscopy abnormalities. <i>Neurological Sciences</i> , 2006, 27, 18-23.	0.9	35
58	Moderate Exercise Improves Cognitive Function in Healthy Elderly People: Results of a Randomized Controlled Trial. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021, 17, 75-80.	0.6	35
59	HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia. <i>PLoS ONE</i> , 2012, 7, e33972.	1.1	34
60	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
61	Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. <i>Acta Myologica</i> , 2013, 32, 7-17.	1.5	33
62	Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin $\alpha$ 2 chain gene: A chance association or a novel phenotype?. <i>Muscle and Nerve</i> , 2011, 44, 826-828.	1.0	32
63	Influence of treatments in multiple sclerosis disability: A cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 433-441.	1.4	32
64	Cladribine vs other drugs in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	32
65	Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis. <i>Leukemia</i> , 2006, 20, 2217-2218.	3.3	31
66	Are <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and Epstein-Barr virus triggers of multiple sclerosis in Sardinia?. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1181-1184.	1.4	31
67	<i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and multiple sclerosis in Sardinian patients: epidemiology and clinical features. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1437-1442.	1.4	31
68	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015, 15, 204.	0.8	31
69	Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1405-1411.	1.8	31
70	Cerebrospinal fluid analysis and the determination of oligoclonal bands. <i>Neurological Sciences</i> , 2017, 38, 217-224.	0.9	30
71	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. <i>Work</i> , 2018, 60, 263-270.	0.6	30
72	Walking in multiple sclerosis improves with tDCS: a randomized, double-blind, sham-controlled study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2310-2319.	1.7	30

#	ARTICLE	IF	CITATIONS
73	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	1.4	30
74	Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. <i>Annals of Hematology</i> , 2004, 83, 403-405.	0.8	29
75	Managing MS in a changing treatment landscape. <i>Journal of Neurology</i> , 2011, 258, 728-739.	1.8	29
76	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2015, 280, 66-68.	1.1	29
77	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. <i>BMC Neurology</i> , 2018, 18, 67.	0.8	27
78	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1297-1303.	0.9	27
79	Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients. <i>Molecular Immunology</i> , 2014, 57, 138-140.	1.0	26
80	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, 1-6.	0.9	26
81	Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0236090.	1.1	26
82	Active elderly and health can moderate exercise improve health and wellbeing in older adults? Protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 331.	0.7	26
83	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	4.5	26
84	EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. <i>Journal of Neuroimmunology</i> , 2013, 264, 120-122.	1.1	25
85	The burden of multiple sclerosis and patients' coping strategies. <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 38-40.	0.8	25
86	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. <i>PLoS ONE</i> , 2013, 8, e59790.	1.1	25
87	Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation. <i>Neurology</i> , 2006, 66, 108-111.	1.5	24
88	Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel LMNA gene mutation. <i>Neuromuscular Disorders</i> , 2008, 18, 291-298.	0.3	24
89	Anti <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 335, 131-133.	0.3	24
90	Antigenic peptide molecular recognition by the DRB1-DQB1 haplotype modulates multiple sclerosis susceptibility. <i>Molecular BioSystems</i> , 2014, 10, 2043-2054.	2.9	24

#	ARTICLE	IF	CITATIONS
91	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon $\beta$ 1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016, 22, 1163-1173.	1.4	24
92	Cognition in multiple sclerosis: Between cognitive reserve and brain volume. <i>Journal of the Neurological Sciences</i> , 2018, 386, 19-22.	0.3	24
93	Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers. <i>BMC Neurology</i> , 2018, 18, 212.	0.8	24
94	Chromosome 7q21 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. <i>Journal of Neuroimmunology</i> , 2002, 125, 141-148.	1.1	23
95	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 975-980.	1.4	23
96	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	1.8	23
97	PML in a person with multiple sclerosis. <i>Neurology</i> , 2018, 90, 83-85.	1.5	23
98	The Relationships between Physical Activity, Self-Efficacy, and Quality of Life in People with Multiple Sclerosis. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2019, 9, 121.	1.0	23
99	Effectiveness and Limitations of Unsupervised Home-Based Balance Rehabilitation with Nintendo Wii in People with Multiple Sclerosis. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	22
100	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing-Remitting and Primary Progressive Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 863.	1.0	22
101	Association of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 203-207.	0.5	22
102	Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. <i>Muscle and Nerve</i> , 2013, 48, 161-170.	1.0	21
103	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. <i>Journal of Neurology</i> , 2018, 265, 424-430.	1.8	21
104	Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. <i>Disability and Rehabilitation</i> , 2018, 40, 144-151.	0.9	21
105	Gait and Functional Mobility in Multiple Sclerosis: Immediate Effects of Transcranial Direct Current Stimulation (tDCS) Paired With Aerobic Exercise. <i>Frontiers in Neurology</i> , 2020, 11, 310.	1.1	21
106	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	0.9	20
107	Induction and Escalation Therapies in Multiple Sclerosis. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2015, 14, 26-34.	1.1	20
108	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case-control MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 74-78.	0.9	20

#	ARTICLE	IF	CITATIONS
109	Cardiac and muscle imaging findings in a family with X-linked Emery-Dreifuss muscular dystrophy. <i>Neuromuscular Disorders</i> , 2012, 22, 152-158.	0.3	19
110	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. <i>Neurological Sciences</i> , 2014, 35, 401-408.	0.9	19
111	Attitude towards physical activity in patients with multiple sclerosis: a cohort study. <i>Neurological Sciences</i> , 2015, 36, 889-893.	0.9	19
112	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	1.4	19
113	Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 132.	3.1	18
114	Serum BAFF levels, Methyprednisolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. <i>Scientific Reports</i> , 2016, 6, 29268.	1.6	18
115	A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.	1.8	18
116	Do gait patterns differ in men and women with multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 202-208.	0.9	18
117	Texting while walking differently alters gait patterns in people with multiple sclerosis and healthy individuals. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 129-133.	0.9	18
118	The Use of Social Media and Digital Devices Among Italian Neurologists. <i>Frontiers in Neurology</i> , 2020, 11, 583.	1.1	18
119	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. <i>Neurological Sciences</i> , 2005, 26, s200-s203.	0.9	17
120	Cardiac involvement in patients with lamin A/C gene mutations: A cohort observation. <i>Muscle and Nerve</i> , 2012, 46, 187-192.	1.0	17
121	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963.	1.4	17
122	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. <i>Neurotherapeutics</i> , 2019, 16, 797-807.	2.1	17
123	A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 143, 120-123.	1.1	16
124	Evolution of the phenotype in a family with an LMNA gene mutation presenting with isolated cardiac involvement. <i>Muscle and Nerve</i> , 2010, 41, 85-91.	1.0	16
125	History of multiple sclerosis in 2 successive pregnancies. <i>Neurology</i> , 2016, 87, 1360-1367.	1.5	16
126	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study. <i>Journal of Neurology</i> , 2019, 266, 2440-2446.	1.8	16



#	ARTICLE	IF	CITATIONS
127	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. <i>Journal of Neurology</i> , 2018, 265, 1328-1333.	1.8	15
128	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1093-1099.	1.0	15
129	Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8848.	1.2	15
130	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 3185-3193.	0.9	15
131	An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1993-2004.	2.0	15
132	A real-world study of alemtuzumab in a cohort of Italian patients. <i>European Journal of Neurology</i> , 2022, 29, 257-266.	1.7	15
133	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. <i>PLoS ONE</i> , 2016, 11, e0163313.	1.1	15
134	ICAM-1 gene is not associated with multiple sclerosis in sardinian patients. <i>Journal of Neurology</i> , 2000, 247, 677-680.	1.8	14
135	Progressive multiple sclerosis and mood disorders. <i>Neurological Sciences</i> , 2015, 36, 1625-1631.	0.9	14
136	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study. <i>Journal of Neurology</i> , 2018, 265, 1096-1101.	1.8	14
137	Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. <i>Journal of Neurology</i> , 2019, 266, 707-716.	1.8	14
138	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	0.9	14
139	The effect of a telerehabilitation virtual reality intervention on functional upper limb activities in people with multiple sclerosis: a study protocol for the TEAMS pilot randomized controlled trial. <i>Trials</i> , 2020, 21, 713.	0.7	14
140	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. <i>Muscle and Nerve</i> , 2014, 49, 928-930.	1.0	13
141	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 799-805.	2.4	13
142	Timed up and go™ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. <i>Journal of Neurology</i> , 2017, 264, 2201-2204.	1.8	13
143	Perception of risk and shared decision making process in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 173-180.	1.4	13
144	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1332-1340.	1.4	13

#	ARTICLE	IF	CITATIONS
145	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	1.4	13
146	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 143, 31-38.	1.1	12
147	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. <i>Journal of Neurology</i> , 2006, 253, 208-213.	1.8	12
148	Role of interferon-beta in <i>Mycobacterium avium</i> subspecies paratuberculosis antibody response in Sardinian MS patients. <i>Journal of the Neurological Sciences</i> , 2015, 349, 249-250.	0.3	12
149	Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach. <i>PLoS ONE</i> , 2019, 14, e0226162.	1.1	12
150	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
151	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 39-49.	1.4	12
152	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. <i>Journal of Neurology</i> , 2004, 251, 1085-8.	1.8	11
153	Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. <i>Neurology</i> , 2005, 65, 490-490.	1.5	11
154	Charcotâ€“Marieâ€“Tooth disease: genetic subtypes in the Sardinian population. <i>Neurological Sciences</i> , 2017, 38, 1019-1025.	0.9	11
155	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. <i>Multiple Sclerosis Journal</i> , 2019, 25, 23-30.	1.4	11
156	The impact of deep grey matter volume on cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102351.	0.9	11
157	Kinematic Analysis of Lower Limb Joint Asymmetry During Gait in People with Multiple Sclerosis. <i>Symmetry</i> , 2021, 13, 598.	1.1	11
158	Efficacy and Safety of Quetiapine Treatment for Delusional Parasitosis. <i>Clinical Neuropharmacology</i> , 2008, 31, 310-312.	0.2	10
159	Aberrant splicing in the <i>LMNA</i> gene caused by a novel mutation on the polypyrimidine tract of intron 5. <i>Muscle and Nerve</i> , 2011, 43, 688-693.	1.0	10
160	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. <i>Neurological Sciences</i> , 2012, 33, 863-867.	0.9	10
161	Evaluation of the humoral response against mycobacterial peptides, homologous to MOC35â€“55, in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2014, 347, 78-81.	0.3	10
162	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 759.	0.9	10

#	ARTICLE	IF	CITATIONS
163	The burden of multiple sclerosis variants in continental Italians and Sardinians. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1385-1395.	1.4	10
164	Effects of Six Months Training on Physical Capacity and Metaboreflex Activity in Patients with Multiple Sclerosis. <i>Frontiers in Physiology</i> , 2016, 7, 531.	1.3	10
165	Long-term follow-up more than 10 years after HSCT: a monocentric experience. <i>Journal of Neurology</i> , 2018, 265, 410-416.	1.8	10
166	Adult brain volume in multiple sclerosis: The impact of paediatric onset. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 21, 103-107.	0.9	10
167	Validation of the Arm Profile Score in assessing upper limb functional impairments in people with multiple sclerosis. <i>Clinical Biomechanics</i> , 2018, 51, 45-50.	0.5	10
168	Association between brain atrophy and cognitive motor interference in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 208-211.	0.9	10
169	What happens after fingolimod discontinuation? A multicentre real-life experience. <i>Journal of Neurology</i> , 2022, 269, 796-804.	1.8	10
170	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	1.8	10
171	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 104-108.	0.9	9
172	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 8-11.	0.9	9
173	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 83-87.	0.9	9
174	Timed Up and Go in men and women with Multiple Sclerosis: Effect of muscular strength. <i>Journal of Bodywork and Movement Therapies</i> , 2020, 24, 124-130.	0.5	9
175	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	2.1	9
176	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.3	9
177	Effects of immersive virtual reality on upper limb function in subjects with multiple sclerosis: A cross-over study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104004.	0.9	9
178	Relationship between gait initiation and disability in individuals affected by multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 594-597.	0.9	8
179	Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon- $\beta$ Therapy in Multiple Sclerosis Patients. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 91-93.	1.1	8
180	Combining HLA-DRB1-DQB1 and Mycobacterium Avium Subspecies Paratuberculosis (MAP) antibodies in Sardinian multiple sclerosis patients: associated or independent risk factors?. <i>BMC Neurology</i> , 2016, 16, 148.	0.8	8

#	ARTICLE	IF	CITATIONS
181	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. <i>Journal of Neuroimmunology</i> , 2017, 313, 89-91.	1.1	8
182	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	1.7	8
183	The impact of secondary infections in COVID-19 critically ill patients. <i>Journal of Infection</i> , 2022, 84, e116-e117.	1.7	8
184	The contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs. <i>Annals of Neurology</i> , 2000, 47, 411-412.	2.8	7
185	Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon $\beta$ 1B. <i>Journal of Neurology</i> , 2005, 252, 1420-1422.	1.8	7
186	Juvenile Multiple Sclerosis Similar to Type I Diabetes Mellitus has a Seasonality of Month of Birth which Differs from that in the General Population. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2008, 21, 473-7.	0.4	7
187	Oxcarbazepine-Induced Leukopenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2008, 20, 502-503.	0.9	7
188	Prevalence of Huntington's disease in Southern Sardinia, Italy. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 54-57.	1.1	7
189	What gait features influence the amount and intensity of physical activity in people with multiple sclerosis?. <i>Medicine (United States)</i> , 2021, 100, e24931.	0.4	7
190	Use of wrist-worn accelerometers to quantify bilateral upper limb activity and asymmetry under free-living conditions in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103081.	0.9	7
191	Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. <i>Frontiers in Immunology</i> , 2021, 12, 728677.	2.2	7
192	Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. <i>Journal of Neurology</i> , 2002, 249, 1552-1555.	1.8	6
193	Variation of the Myelin Oligodendrocyte Glycoprotein gene is not primarily associated with multiple sclerosis in the Sardinian population. <i>BMC Genetics</i> , 2007, 8, 25.	2.7	6
194	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. <i>Journal of the Neurological Sciences</i> , 2015, 357, 229-234.	0.3	6
195	The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 174-178.	0.9	6
196	Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. <i>European Journal of Neurology</i> , 2018, 25, 1063-1068.	1.7	6
197	Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-6.	0.4	6
198	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. <i>PLoS ONE</i> , 2019, 14, e0226615.	1.1	6

#	ARTICLE	IF	CITATIONS
199	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. <i>Disability and Rehabilitation</i> , 2020, 42, 737-742.	0.9	6
200	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102145.	0.9	6
201	Listening to the neurological teams for multiple sclerosis: the SMART project. <i>Neurological Sciences</i> , 2020, 41, 2231-2240.	0.9	6
202	IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients. <i>Microorganisms</i> , 2020, 8, 500.	1.6	6
203	Detection of disability worsening in relapsing&#x2013;remitting multiple sclerosis patients: a real&#x2013;world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021, 28, 567-578.	1.7	6
204	Event-related potentials and deep grey matter atrophy in multiple sclerosis: Exploring the possible associations with cognition. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102785.	0.9	6
205	Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil. <i>Experimental Neurology</i> , 2022, 347, 113906.	2.0	6
206	Comparing natural history of early and late onset pediatric multiple sclerosis. <i>Annals of Neurology</i> , 2022, , .	2.8	6
207	Inter-joint coordination during gait in people with multiple sclerosis: A focus on the effect of disability. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103741.	0.9	6
208	Is multiple sclerosis severity a genetically influenced trait?. <i>Neurological Sciences</i> , 2000, 21, S843-S847.	0.9	5
209	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 65-67.	0.9	5
210	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102564.	0.9	5
211	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. <i>Frontiers in Immunology</i> , 2022, 13, 818325.	2.2	5
212	The cohort of the multiple sclerosis center of Cagliari. <i>Neurological Sciences</i> , 2011, 31, 309-312.	0.9	4
213	Oral Agents in Multiple Sclerosis. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2015, 14, 15-25.	1.1	4
214	Mitoxantrone exposure in pregnancy: a new case report in a multiple sclerosis patient. <i>Case Reports in Perinatal Medicine</i> , 2016, 5, 125-126.	0.1	4
215	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020, 29, 783-791.	1.5	4
216	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	0.9	4

#	ARTICLE	IF	CITATIONS
217	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103909.	0.9	4
218	Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1030-1036.	1.4	3
219	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. <i>Neurological Sciences</i> , 2013, 34, 197-203.	0.9	3
220	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. <i>Multiple Sclerosis Journal</i> , 2018, 24, 231-233.	1.4	3
221	Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. <i>Neurological Sciences</i> , 2018, 39, 389-390.	0.9	3
222	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101886.	0.9	3
223	Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. <i>Functional Neurology</i> , 2006, 21, 145-9.	1.3	3
224	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	1.4	3
225	Cyclograms Reveal Alteration of Inter-Joint Coordination during Gait in People with Multiple Sclerosis Minimally Disabled. <i>Biomechanics</i> , 2022, 2, 331-341.	0.5	3
226	Cortical Pathology in RRMS: Taking a Cue from Four Sisters. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-6.	0.4	2
227	Long-term benefits of induction therapy in NMO: a case report. <i>Neurological Sciences</i> , 2014, 35, 1831-1832.	0.9	2
228	Brain volume in early MS patients with and without IgG oligoclonal bands in CSF. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 55-58.	0.9	2
229	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
230	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 224.	1.0	2
231	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. <i>Frontiers in Neurology</i> , 2021, 12, 679355.	1.1	2
232	A Novel Mutation in Lamin A/C Gene: Phenotype and Consequences on the Protein Structure and Flexibility. <i>SRX Biology</i> , 2010, 2010, 1-7.	0.0	2
233	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. <i>Biomolecules</i> , 2022, 12, 677.	1.8	2
234	Muscle <sc>MRI</sc> in female carriers of emerinopathy. <i>European Journal of Neurology</i> , 2013, 20, e127.	1.7	1

#	ARTICLE	IF	CITATIONS
235	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. <i>Neurological Sciences</i> , 2015, 36, 2213-2220.	0.9	1
236	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107.	1.8	1
237	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
238	Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I. <i>Frontiers in Medicine</i> , 2020, 7, 163.	1.2	1
239	Geographic differences in the incidence of Huntington's disease in Sardinia, Italy. <i>Neurological Sciences</i> , 2021, 42, 5177-5181.	0.9	1
240	Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers. <i>Frontiers in Neurology</i> , 2021, 12, 636463.	1.1	1
241	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110590.	0.5	1
242	Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1192-1192.	0.9	0
243	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.	0.9	0
244	EDSS trajectories in multiple sclerosis patients from the Italian MS register. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117824.	0.3	0
245	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117749.	0.3	0
246	TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy. <i>Current Medical Imaging</i> , 2017, 14, 95-98.	0.4	0